Professional
Technical
In the Industry Vocabulary Test
PDL1
Also written as: PDL1 — Programmed Death-Ligand 1
A protein that helps cancer cells evade immune system detection, commonly tested to predict immunotherapy response.
Full Definition
Programmed Death-Ligand 1 (PDL1) is a transmembrane protein that serves as a checkpoint inhibitor, allowing cancer cells to escape immune surveillance. When PDL1 binds to its receptor PD-1 on T cells, it suppresses the immune response against tumor cells. PDL1 expression levels, measured through immunohistochemistry, serve as a predictive biomarker for response to immune checkpoint inhibitors such as pembrolizumab and nivolumab in various cancer types.
Usage
Usage note: May be written as PD-L1 or PDL1; maintain consistency within documents.
In Context
- "Immunohistochemistry revealed PDL1 expression in 75% of tumor cells, indicating potential benefit from checkpoint inhibitor therapy." — Pathology report
- "PDL1 testing is now standard practice for selecting patients with advanced non-small cell lung cancer for immunotherapy." — Clinical guideline
Also known as
PD-L1
Programmed Death-Ligand 1
Don't confuse with
PD1
PDL2